scholarly journals Statin related musculoskeletal complications; Necrotizing Autoimmune Myositis… more than Myalgia.

2021 ◽  
Author(s):  
William Scheuing ◽  
Dadhania Dadhania ◽  
adegbenga Bankole
Keyword(s):  
Side Effects ◽  
Immunosuppressive Therapy ◽  
Nocebo Effect ◽  
Autoimmune Myositis ◽  
Immune Mediated ◽  
Necrotizing Myositis

Statins are widely prescribed and well tolerated with most side effects now considered a nocebo effect. Occasionally, statins can be associated with immune mediated necrotizing myositis that is both difficult to diagnose and treat. Aggressive immunosuppressive therapy is the best recognized method of treatment of this complication.

Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab

2021 ◽  
pp. 112067212199104
Author(s):  
Catherine J Hwang ◽  
Erin E Nichols ◽  
Brian H Chon ◽  
Julian D Perry
Keyword(s):  
Side Effects ◽  
Optic Neuropathy ◽  
Surgical Decompression ◽  
Thyroid Eye Disease ◽  
Eye Disease ◽  
High Dose ◽  
Compressive Optic Neuropathy ◽  
Traditional Management ◽  
Immune Mediated ◽  
Orbital Radiation

Thyroid eye disease is an auto-immune mediated orbitopathy which can cause dysthyroid compressive optic neuropathy. Traditional management of active thyroid eye disease includes temporizing high-dose steroids, orbital radiation and surgical decompression, which each possess significant limitations and/or side effects. Teprotumumab is an IGF-IR inhibitor recently FDA-approved for active thyroid eye disease. The authors report reversal of bilateral dysthyroid compressive optic neuropathy managed medically utilizing teprotumumab.

Immunosuppressive therapy of biopsy proved immune-mediated lymphocytic myocarditis in the virus-negative and virus-positive patients.

2020 ◽  
Vol 49 ◽  
pp. 107260
Author(s):  
Olga Blagova ◽  
Alexander Nedostup ◽  
Evgeniya Kogan ◽  
Alexander Zaitsev ◽  
Victor Fomin
Keyword(s):  
Immunosuppressive Therapy ◽  
Immune Mediated ◽  
Lymphocytic Myocarditis

Autoimmunity associated with immunotherapy of cancer

Blood ◽  
2011 ◽  
Vol 118 (3) ◽  
pp. 499-509 ◽  
Author(s):  
Sally M. Amos ◽  
Connie P. M. Duong ◽  
Jennifer A. Westwood ◽  
David S. Ritchie ◽  
Richard P. Junghans ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Side Effects ◽  
Cell Transfer ◽  
Serious Adverse Events ◽  
Normal Tissues ◽  
Immune Mediated ◽  
Organ Systems ◽  
Immunotherapy Of Cancer ◽  
Future Potential

Abstract In this age of promise of new therapies for cancer, immunotherapy is emerging as an exciting treatment option for patients. Vaccines and cytokines are being tested extensively in clinical trials, and strategies using monoclonal antibodies and cell transfer are mediating dramatic regression of tumors in patients with certain malignancies. However, although initially advocated as being more specific for cancer and having fewer side effects than conventional therapies, it is becoming increasingly clear that many immunotherapies can lead to immune reactions against normal tissues. Immunotoxicities resulting from treatment can range from relatively minor conditions, such as skin depigmentation, to severe toxicities against crucial organ systems, such as liver, bowel, and lung. Treatment-related toxicity has correlated with better responses in some cases, and it is probable that serious adverse events from immune-mediated reactions will increase in frequency and severity as immunotherapeutic approaches become more effective. This review introduces immunotherapeutic approaches to cancer treatment, provides details of toxicities arising from therapy, and discusses future potential ways to avoid or circumvent these side effects.

scholarly journals A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis

2018 ◽  
Vol 4 (4) ◽  
pp. 205521731881901 ◽  
Author(s):  
Patrick Aouad ◽  
Con Yiannikas ◽  
Suran L Fernando ◽  
John Parratt
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Cycle ◽  
The Other ◽  
High Efficacy ◽  
Distinct Entity ◽  
Disease Modifying Therapy ◽  
Autoimmune Myositis ◽  
Immune Mediated ◽  
Oral Corticosteroids ◽  
Disease Modifying

Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms of multiple sclerosis and is associated with secondary autoimmune adverse events. We report a novel case of secondary autoimmune myositis that occurred seven months after the initial treatment cycle and achieved full recovery with oral corticosteroids. This particular form of myositis appears to be unique, and is likely to be a distinct entity from the other four types of immune-mediated myositis.

Canine immune-mediated diabetes mellitus: a case report

1995 ◽  
Vol 31 (4) ◽  
pp. 295-299 ◽  
Author(s):  
M Elie ◽  
M Hoenig
Keyword(s):  
Diabetes Mellitus ◽  
Case Report ◽  
Beta Cell ◽  
Immunosuppressive Therapy ◽  
Hemolytic Anemia ◽  
Predictive Marker ◽  
Severe Anemia ◽  
Specific Antibodies ◽  
Time Treatment ◽  
Immune Mediated

A four-year-old, spayed female toy fox terrier presented with hyperglycemia and severe anemia. A diagnosis of immune-mediated diabetes mellitus was made based upon the finding of beta-cell specific antibodies. Immune-mediated hemolytic anemia was diagnosed based on findings of a regenerative anemia, spherocytosis, hyperbilirubinemia, hemoglobinuria, and bilirubinuria. The anemia resolved following two months of immunosuppressive therapy. The diabetes was treated with insulin for four months, after which time treatment was no longer necessary. However, the dog remained positive for beta-cell antibodies which may be a predictive marker for the recurrence of diabetes mellitus in the future.

Retinopathy Associated with Adjuvant Interferon in a Patient with Malignant Melanoma: A Case Report and Review of the Literature

2019 ◽  
pp. 1-7
Author(s):  
Mahmut Dogan
Keyword(s):  
Multiple Sclerosis ◽  
Visual Acuity ◽  
Side Effects ◽  
Vision Loss ◽  
Interferon Treatment ◽  
Ocular Toxicity ◽  
Review Of The Literature ◽  
Immune Mediated ◽  
Adjuvant Interferon

Interferons are kinds of proteins with immuneregulatory, antiviral and anti-proliferative functions. Interferons are widely used worldwide for the treatment of many diseases including cancer, hepatit C and immune mediated disease such as multiple sclerosis. Long-term use of interferons have some side effects. However, interferons have ophthalmologic side effects. Ocular toxicity may occur at any time during treatment. There is no association between the dose or duration of interferon treatment and ocular toxicity. Although visual acuity returns to normal in most patients when interferon is discontinued, vision loss may be permanent.

Sign in / Sign up

Export Citation Format

Share Document